NYSE:NBY NovaBay Pharmaceuticals (NBY) Stock Price, News & Analysis → The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad) Free NBY Stock Alerts $0.08 0.00 (0.00%) (As of 04/17/2024 ET) Add Compare Share Share Today's Range$0.08▼$0.1050-Day Range$0.08▼$0.1752-Week Range$0.07▼$1.95Volume13.45 million shsAverage Volume3.46 million shsMarket Capitalization$2.93 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsOwnershipSEC FilingsSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsOwnershipSEC FilingsSocial Media Get NovaBay Pharmaceuticals alerts: Email Address Ad Paradigm PressCould Bitcoin Literally FORCE This Crypto To Rocket Up?Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…>>Click here to find out what it is. About NovaBay Pharmaceuticals Stock (NYSE:NBY)NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through traditional and digital beauty retailers and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.Read More NBY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NBY Stock News HeadlinesApril 15, 2024 | americanbankingnews.comNovaBay Pharmaceuticals (NYSE:NBY) Now Covered by Analysts at StockNews.comMarch 28, 2024 | seekingalpha.comNovaBay Pharmaceuticals, Inc. (NBY) Q4 2023 Earnings Call TranscriptApril 18, 2024 | Gold Safe Exchange (Ad)The “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.March 26, 2024 | benzinga.comNovaBay Pharmaceuticals: Q4 Earnings InsightsMarch 26, 2024 | finance.yahoo.comNovaBay Pharmaceuticals Reports 2023 Fourth Quarter and Full Year Financial ResultsMarch 25, 2024 | businesswire.comNovaBay Pharmaceuticals to Hold 2023 Fourth Quarter and Full Year Conference Call on March 26, 2024March 14, 2024 | businesswire.comNovaBay Pharmaceuticals Announces Agreement to Sell its DERMAdoctor Skincare Business Segment; Announces Preliminary Financial Results for Fourth Quarter and Year Ended December 31, 2023February 21, 2024 | markets.businessinsider.comNioBay Metals closes option agreement to acquire Foothills propertySee More Headlines Receive NBY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NovaBay Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/26/2024Today4/17/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSE:NBY CUSIPN/A CIK1389545 Webnovabay.com Phone510-899-8800Fax510-474-1577Employees24Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($3.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-9,640,000.00 Net Margins-65.46% Pretax Margin-65.46% Return on Equity-150.14% Return on Assets-53.48% Debt Debt-to-Equity RatioN/A Current Ratio1.67 Quick Ratio1.00 Sales & Book Value Annual Sales$14.73 million Price / Sales0.20 Cash FlowN/A Price / Cash FlowN/A Book Value$0.12 per share Price / Book0.69Miscellaneous Outstanding Shares36,060,000Free Float35,592,000Market Cap$2.99 million OptionableNot Optionable Beta1.97 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Justin M. Hall Esq. (Age 46)President, CEO, General Counsel, Chief Compliance Officer, Corporate Secretary & Director Comp: $364.15kMr. Tommy Law (Age 39)Controller, Interim CFO & Treasurer Comp: $155.48kKey CompetitorsAraviveNASDAQ:ARAVRevelation BiosciencesNASDAQ:REVBPhio PharmaceuticalsNASDAQ:PHIO60 Degrees PharmaceuticalsNASDAQ:SXTPTransCode TherapeuticsNASDAQ:RNAZView All CompetitorsInstitutional OwnershipArmistice Capital LLCBought 718,768 shares on 2/13/2024Ownership: 11.007%View All Institutional Transactions NBY Stock Analysis - Frequently Asked Questions How have NBY shares performed in 2024? NovaBay Pharmaceuticals' stock was trading at $0.2040 at the beginning of the year. Since then, NBY stock has decreased by 60.2% and is now trading at $0.0812. View the best growth stocks for 2024 here. How were NovaBay Pharmaceuticals' earnings last quarter? NovaBay Pharmaceuticals, Inc. (NYSE:NBY) posted its quarterly earnings data on Tuesday, March, 26th. The company reported ($0.95) EPS for the quarter. The company had revenue of $3.73 million for the quarter. NovaBay Pharmaceuticals had a negative net margin of 65.46% and a negative trailing twelve-month return on equity of 150.14%. What other stocks do shareholders of NovaBay Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other NovaBay Pharmaceuticals investors own include OpGen (OPGN) and Abbott Laboratories (ABT). How do I buy shares of NovaBay Pharmaceuticals? Shares of NBY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:NBY) was last updated on 4/18/2024 by MarketBeat.com Staff From Our Partners[Urgent!] Generational Wealth GameplanCrypto 101 MediaHe Is Giving Away BitcoinCrypto Swap ProfitsThe “Perfect Storm” for GoldGold Safe ExchangeUrgent alert: open this for a huge profit potentialTimothy SykesTop 5 AI Stocks to Buy for 2024Market Moving TrendsBiden out June 13; Kamala won’t replace him?Paradigm PressThe #1 Crypto for 2024InvestorPlaceOptions trading has suddenly become more reliable.Eagle Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NovaBay Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.